FibroBiologics Inc. Files Amendment 6 to S-1 Registration Statement

TL;DR

<b>FibroBiologics, Inc. has filed an amendment to its S-1 registration statement, indicating progress in its public offering process.</b>

AI Summary

FibroBiologics Inc. (FBLG) filed a Amended IPO Registration (S-1/A) with the SEC on January 22, 2024. FibroBiologics, Inc. filed Amendment No. 6 to its Form S-1 Registration Statement on January 22, 2024. The company is incorporated in Delaware and its principal executive offices are located in Houston, Texas. The filing is related to the Securities Act of 1933, with registration number 333-275361. FibroBiologics, Inc. is classified as a pharmaceutical preparations company. The company has elected to use the extended transition period for complying with new or revised financial accounting standards.

Why It Matters

For investors and stakeholders tracking FibroBiologics Inc., this filing contains several important signals. This amendment signifies ongoing efforts by FibroBiologics to become a publicly traded company, which could provide access to capital for research and development or expansion. The filing details the company's structure, location, and regulatory compliance, providing transparency for potential investors and stakeholders.

Risk Assessment

Risk Level: low — FibroBiologics Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, not a new offering or financial report, thus carrying minimal immediate risk.

Analyst Insight

Monitor future filings for updates on the S-1 effectiveness and details of the proposed public offering.

Key Numbers

• 6 — Amendment Number (Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT)
• 2024-01-22 — Filing Date (Filed as of date: 20240122)
• 2834 — SIC Code (Primary Standard Industrial Classification Code Number)
• 86-3329066 — IRS Number (I.R.S. Employer Identification Number)

Key Players & Entities

• FibroBiologics Inc. (company) — Filer name
• Pete O'Heeron (person) — Chief Executive Officer
• Norton Rose Fulbright US LLP (company) — Legal counsel
• Brian Fenske (person) — Contact for legal counsel
• 281-671-5152 (dollar_amount) — Business phone number
• 333-275361 (dollar_amount) — SEC file number

Forward-Looking Statements

• FibroBiologics Inc. will complete its initial public offering (IPO) (FibroBiologics Inc.) — medium confidence, target: 2024-12-31

FAQ

Industry Context

FibroBiologics operates in the pharmaceutical preparations industry, focusing on the development and commercialization of regenerative medicine products.

Regulatory Implications

The company is filing under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

1. Review the full S-1/A filing for details on the proposed securities offering.
2. Track subsequent amendments or effectiveness notices for the registration statement.
3. Analyze the company's business strategy and financial projections once disclosed in the offering prospectus.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating updates or additions to the initial registration statement.

Filing Documents

• forms-1a.htm (S-1/A) — 120KB
• ex10-23.htm (EX-10.23) — 100KB
• ex10-23_001.jpg (GRAPHIC) — 28KB
• 0001493152-24-003183.txt (&nbsp;) — 260KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Houston, State of Texas, on January 22, 2024. FibroBiologics, Inc. By: /s/ Pete O&rsquo;Heeron Pete O&rsquo;Heeron Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. Signature Title Date /s/ Pete O&rsquo;Heeron Chairperson and Chief Executive Officer January 22, 2024 Pete O&rsquo;Heeron (Principal Executive Officer) /s/ Mark Andersen Chief Financial Officer January 22, 2024 Mark Andersen (Principal Financial Officer and Principal Accounting Officer) * Director January 22, 2024 Robert Hoffman * Director January 22, 2024 Victoria Niklas, M.D. * Director January 22, 2024 Richard Cilento * Director January 22, 2024 Stacy Coen * Director January 22, 2024 Matthew Link *By: /s/ Mark Andersen Name: Mark Andersen Title: Attorney-in-fact II-4

View Full Filing

View this S-1/A filing on SEC EDGAR